TARA
NASDAQ · Biotechnology
Protara Therapeutic Inc
$5.21
-0.09 (-1.70%)
Financial Highlights (FY 2025)
Revenue
193.62M
Net Income
-27,587,371
Gross Margin
53.0%
Profit Margin
-14.3%
Rev Growth
+24.4%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 53.0% | 53.0% | 53.0% |
| Operating Margin | -17.4% | -17.8% | -15.1% |
| Profit Margin | -14.3% | -14.2% | -16.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 193.62M | 202.51M | 206.29M |
| Gross Profit | 102.70M | 107.42M | 109.43M |
| Operating Income | -33,593,474 | -35,950,951 | -31,127,578 |
| Net Income | -27,587,371 | -28,749,471 | -33,771,699 |
| Gross Margin | 53.0% | 53.0% | 53.0% |
| Operating Margin | -17.4% | -17.8% | -15.1% |
| Profit Margin | -14.3% | -14.2% | -16.4% |
| Rev Growth | +24.4% | +2.2% | +1.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 67.58M | 63.28M | 75.92M |
| Total Equity | 258.99M | 281.95M | 255.39M |
| D/E Ratio | 0.26 | 0.22 | 0.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -51,862,975 | -48,122,998 | -52,884,989 |
| Free Cash Flow | -39,587,712 | -47,283,878 | -36,549,207 |